澳股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

DIMERIX LTD

0.315

+0.0051.61%

成交量：58.71万

成交额：18.23万

市值：1.89亿

市盈率：-11.26

高：0.315

开：0.305

低：0.305

收：0.310

52周最高：0.665

52周最低：0.157

股本：6.00亿

流通股本：4.68亿

量比：0.43

换手率：0.13%

股息：- -

股息率：- -

每股收益(TTM):-0.028

每股收益(LYR):-0.024

净资产收益率：-594.54%

总资产收益率：-58.27%

市净率：-112.50

市盈率(LYR):-13.32

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

DIMERIX LTD

交易所：

ASX

成立时间：

- -

员工人数：

15

公司地址：

425 Smith Street,Fitzroy,Victoria,Australia

官网：

http://dimerix.com

邮编：

3065

电话：

传真：

61 8 9388 8256

简介：

Dimerix Limited, a clinical stage biotechnology company, develops and commercializes new therapies in the area of unmet medical needs. Its lead product candidate is DMX-200, which is in Phase II clinical trial for the treatment of diabetic kidney diseases and focal segmental glomerulosclerosis. The company is headquartered in Fitzroy, Australia.

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/stock/DXB.AU/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DXB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","market":"AU","secType":"STK","nameCN":"DIMERIX LTD","latestPrice":0.315,"timestamp":1787638320000,"preClose":0.31,"halted":0,"volume":587104,"delay":0,"changeRate":0.01612903225806453,"nameEN":"DIMERIX LTD","floatShares":467696880,"shares":600396776,"eps":-0.027967,"marketStatus":"未开盘","change":0.005,"latestTime":"08-25 16:12:00 AEST","open":0.305,"high":0.315,"low":0.305,"amount":182343,"amplitude":0.032258,"askPrice":0.315,"askSize":1686,"bidPrice":0.31,"bidSize":57809,"shortable":3,"etf":0,"ttmEps":-0.027967,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.31,"openAndCloseTimeList":[[1787616000000,1787637600000]],"volumeRatio":0.4288291604388187,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"DXB.AU","preClose":0.31,"auctionPrice":0.315,"auctionVolume":8225,"auction":3,"marketStatus":"盘后竞价","timestamp":1787638203501}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","floatShares":467696880,"roa":"-58.27%","roe":"-594.54%","lyrEps":-0.023645,"volumeRatio":0.4288291604388187,"shares":600396776,"dividePrice":0,"high":0.315,"amplitude":0.032258,"preClose":0.31,"low":0.305,"week52Low":0.157,"pbRate":"-112.50","psRate":"25.50","week52High":0.665,"institutionHeld":0,"latestPrice":0.315,"committee":0.943323,"eps":-0.027967,"divideRate":0,"volume":587104,"delay":0,"ttmEps":-0.027967,"open":0.305,"prevYearClose":0.55,"prevWeekClose":0.31,"prevMonthClose":0.245,"prevQuarterClose":0.205,"fiveDayClose":0.295,"twentyDayClose":0.25,"sixtyDayClose":0.185,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DXB.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DXB.AU\",market:\"AU\",,,undefined,":[],"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":23928564,"employeeNum":15,"address":"425 Smith Street,Fitzroy,Victoria,Australia","zipCode":"3065","officePhone":"1300 813 321","officeFax":"61 8 9388 8256","fiscalYearEnd":"06-30"},"stockCompanyDetail":{"websiteUrl":"http://dimerix.com","stockEarnings":[{"period":"1week","weight":0.0678},{"period":"1month","weight":0.26},{"period":"3month","weight":0.7027},{"period":"6month","weight":-0.3077},{"period":"1year","weight":-0.3226},{"period":"ytd","weight":-0.4273}],"compareEarnings":[{"period":"1week","weight":0.0117},{"period":"1month","weight":0.0326},{"period":"3month","weight":0.0637},{"period":"6month","weight":0.0332},{"period":"1year","weight":0.0993},{"period":"ytd","weight":0.0637}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Dimerix Limited, a clinical stage biotechnology company, develops and commercializes new therapies in the area of unmet medical needs. Its lead product candidate is DMX-200, which is in Phase II clinical trial for the treatment of diabetic kidney diseases and focal segmental glomerulosclerosis. The company is headquartered in Fitzroy, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.181818,"avgChangeRate":-0.092931},{"month":2,"riseRate":0.454545,"avgChangeRate":0.020467},{"month":3,"riseRate":0.363636,"avgChangeRate":0.019402},{"month":4,"riseRate":0.272727,"avgChangeRate":0.014529},{"month":5,"riseRate":0.545455,"avgChangeRate":0.055282},{"month":6,"riseRate":0.818182,"avgChangeRate":0.166318},{"month":7,"riseRate":0.333333,"avgChangeRate":0.083729},{"month":8,"riseRate":0.363636,"avgChangeRate":-0.063764},{"month":9,"riseRate":0.363636,"avgChangeRate":0.171129},{"month":10,"riseRate":0.181818,"avgChangeRate":-0.090222},{"month":11,"riseRate":0.272727,"avgChangeRate":0.028595},{"month":12,"riseRate":0.454545,"avgChangeRate":0.04297}],"exchange":"ASX","name":"DIMERIX LTD","nameEN":"DIMERIX LTD"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"DXB.AU\",market:\"AU\",,,undefined,":null}}